Casdin Capital, LLC Beam Therapeutics Inc. Transaction History

Casdin Capital, LLC

$855 Million
Q1 2025

A detailed history of Casdin Capital, LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Casdin Capital, LLC holds 1,425,562 shares of BEAM stock, worth $25.3 Million. This represents 3.26% of its overall portfolio holdings.

Number of Shares

1,425,562

Previous 1,250,000 14.04%

Holding current value

$25.3 Million

Previous $31 Million 10.19%

% of portfolio

3.26%

Previous 2.67%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$19.53 - $34.09 $3.43 Million - $5.98 Million	175,562 Added 14.04%	1,425,562 $27.8 Million
Q4 2024 Feb 14, 2025	BUY	$21.55 - $30.35 $10.2 Million - $14.4 Million	475,000 Added 61.29%	1,250,000 $31 Million
Q3 2024 Nov 14, 2024	BUY	$22.57 - $33.14 $2.26 Million - $3.31 Million	100,000 Added 14.81%	775,000 $19 Million
Q1 2024 May 15, 2024	BUY	$23.46 - $45.07 $3.45 Million - $6.63 Million	147,000 Added 27.84%	675,000 $22.3 Million
Q4 2023 Feb 14, 2024	SELL	$17.69 - $30.76 $742,980 - $1.29 Million	-42,000 Reduced 7.37%	528,000 $14.4 Million
Q1 2023 May 15, 2023	BUY	$30.15 - $48.79 $6.03 Million - $9.76 Million	200,000 Added 54.05%	570,000 $17.5 Million
Q3 2022 Nov 14, 2022	SELL	$39.79 - $70.31 $198,950 - $351,550	-5,000 Reduced 1.33%	370,000 $17.6 Million
Q2 2022 Aug 15, 2022	SELL	$29.86 - $62.36 $13.3 Million - $27.7 Million	-443,820 Reduced 54.2%	375,000 $14.5 Million
Q1 2021 May 17, 2021	BUY	$71.28 - $120.75 $25.6 Million - $43.3 Million	358,820 Added 78.0%	818,820 $65.5 Million
Q4 2020 Feb 16, 2021	BUY	$22.24 - $95.63 $10.2 Million - $44 Million	460,000 New	460,000 $37.6 Million

Others Institutions Holding BEAM

# of Institutions

258

Shares Held

93.6M

Call Options Held

425K

Put Options Held

309K

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.25B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Casdin Capital, LLC with notifications on news.

Account

Casdin Capital, LLC Beam Therapeutics Inc. Transaction History